Method : In this study we sought to characterize the relationship between several pharmacokinetic and pharmacodynamic parameters and virologic responses among HIV/hepatitis C virus genotype-1 co-infected patients receiving pegylated interferonalpha-2b (peg-IFN2b) and ribavirin. We also tried to establish the underlying mechanisms that lead to poor sustained virologic responder rates observed with African-Americans against Caucasians and compared their results with those observed in a cohort of hepatitis C virus mono-infected patients.
Introduction
Infection by hepatitis C virus (HCV) is commonly complicated by co-infection with HIV due to shared routes of transmission [1] . HCV co-infection also plays a major role in morbidity and mortality of HIV-infected individuals. HCV co-infection is seen in 15-30% of all HIV-infected individuals in the United States and Western Europe, with more than 250 000 individuals affected in the United States [1, 2] . The introduction of antiretroviral therapy (ART) has improved clinical outcomes in patients infected with HIV [3]; however, liver disease has become a leading cause of morbidity and mortality in this population [4] [5] [6] [7] . HIV infection is also associated with higher HCV viral levels in serum [8] and a rapid progression of liver disease among those who are also co-infected with HCV [9] . Several serious adverse events associated with ART are exacerbated in HCV/ HIV co-infected individuals, making it difficult to accomplish adequate virologic control of HIV [10] [11] [12] [13] . Although combination therapy with pegylated interferon (peg-interferon) and ribavirin has resulted in higher cure rates among HCV mono-infected individuals [14, 15] , HIV co-infected individuals have only modest responses to therapy [16] [17] [18] [19] [20] [21] . Furthermore, several studies of HCV mono-infected individuals have shown that the overall cure rates observed with African-Americans are much lower than Caucasians [15, 22] . Nevertheless, the reason for the poor response in African-Americans is still not understood, and its extent in co-infected patients is not clear. Characterizing the determinants of this decreased response among HIV-HCV co-infected patients, particularly African-Americans, may thus aid in optimizing therapeutic outcome.
Previously it has been shown that biphasic HCV viral kinetics have predictive ability for sustained virologic responders (SVR)s among HCV mono-infected individuals [23, 24] . Recently, it has also been shown that monitoring HCV viral kinetics has similar predictive ability among HIV/HCV co-infected individuals as well [25, 26] . Some studies have also shown the clinical significance of early virologic response (week 4 and week 8 viral responses) in predicting an SVR among HCV/ HIV co-infected individuals treated with peg-interferon and ribavirin [27] [28] [29] . Several factors including IFN-a pharmacokinetics have been shown to play a major role as the determinants of SVR among HCV mono-infected individuals treated with combination therapy (reviewed in [30] ). Recently, a combination of factors including viral kinetics and interferon pharmacokinetic parameters, defined as pharmacodynamic factors, were found to be useful in predicting SVR [31] . Studies in HCV/HIV coinfected patients treated with interferon and ribavirin have demonstrated a relationship between the pharmacodynamics (a combination of viral kinetics and interferon pharmacokinetic parameters) of peg-IFN-a and virologic response [31] . A recent study has also suggested possible differences in pharmacodynamics and viral kinetics between different racial groups [31] . However, these studies have not systematically addressed the nature of HCV viral kinetics and pharmacodynamics in predicting SVR among HIV/HCV co-infected individuals, particularly between African-Americans and Caucasians. Furthermore, no comparison was yet attempted between the pharmacodynamics in HCV mono-infected versus co-infected patients.
Methods

Study design
The study was a pilot, prospective, open-label trial performed at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) at Bethesda, Maryland from 2001 to 2004. Twentythree HIV/HCV genotype 1 co-infected patients were treated with peg-IFNa2b at 1.5 mg/kg subcutaneously every week (Peg-Intron; Schering-Plough, Kenilworth, New Jersey, USA) and ribavirin daily (Rebetol; Schering-Plough, at 400 mg Qam and 600 mg Qpm for <75 kg, 600 mg twice per day for >75 kg) for 48 weeks and followed up for 24 weeks after the end of treatment. All patients were receiving ART. All patients signed informed consent approved by the NIAID institutional review board prior to enrollment in the study.
Study patients
Patients were eligible for the study if they were more than 18 years of age and had CD4 þ T-cell counts greater than 100 cells/ml, absolute neutrophil counts greater than 1000 cells/ml, HCV viral load more than 2000 copies/ml, infected with HCV genotype 1, had no prior IFN-abased treatment and had histologic evidence of chronic hepatitis C.
Laboratory studies
Liver chemistry and safety laboratory tests were performed prior to treatment and during each study visit. HCV RNA was measured during all study visits (days 0, 1, 3, 5, 7, 10, week 2, week 3, week 4, week 6, week 8, and then every 4 weeks until week 48). HCV RNA concentration in plasma was measured by VERSANT HCV RNA 3.0 Assay (Bayer Diagnostics, Puteaux, France). The assay has a quantitation range of 615-7.7 Â 10 6 HCV RNA IU/ml. Sustained virologic response was determined by a negative qualitative RNA PCR at 72 weeks.
Measurement of serum peg-interferon-alpha 2b concentrations
Peg-IFNa2b concentrations were determined by application of a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) method (Bender MedSystems Diagnostics GmbH, Vienna, Austria). The assay uses a murine anti-human IFNa monoclonal antibody adsorbed onto micro wells, which captures IFNa present in the samples or controls. A horseradish peroxidaseconjugated monoclonal anti-IFNa antibody binds to captured IFNa. After addition of substrate, interferon concentration is determined colorimetrically. Calibration curves were prepared by plotting the optical density versus the concentration of the standards. Standards from 78 to 10 000 pg/ml were prepared by diluting peg-IFNa2b in normal human serum (CLB, Amsterdam, The Netherlands). Plasma samples were diluted five times and tested on the same plates as the standards. All calibration standards, quality control samples, and study samples were analyzed in duplicate. The detection limit of the assay was 100 pg/ml and the assay was linear up to a concentration of 5000 pg/ml. The interassay coefficients of variation of standards and quality control samples did not exceed 20%. Peginterferon concentrations were measured at days 0, 1, 3, 5, 7, 10, 14, 21, 28, 42, 56, and 84.
Modeling viral kinetics, pharmacokinetics, and pharmacodynamics
Hepatitis C virus viral kinetics were calculated using a modification of a model previously described by Neumann et al. [23] :
where T(t) represents target cells, I(t) represents productively infected cells, and V(t) free virus. S T represents the source rate of target cells and d T their loss rate constant; b is the de-novo infection rate constant; p is the rate of virion release/production from each infected cell; d is the infected cells loss rate constant with infected cells half-life of ln(2)/d; c is the intrinsic clearance rate constant of free virus with free virions half-life of ln(2)/c.
According to Neumann et al. [23] , the antiviral effect of IFNa is mainly in blocking of viral production from infected cells (with effectiveness 0 < e 1), thus we approximated that blocking de-novo infection is negligible (h ¼ 0) [23] .
As a result of weekly peg-interferon injections, IFNa has nonconstant levels during the week until the next injection, in contrast to the assumption of approximately constant drug level made by Neumann et al. [23] . Therefore, we modified the model to allow the antiviral effectiveness, e, to vary with time as a Hill function of peg-interferon concentration (similar to [31] [32] [33] ):
eðtÞ ¼ e max Â CðtÞ n CðtÞ n þ EC n 50 (4) where e max is a constant maximal individual efficacy that can be reached during peg-interferon treatment, EC 50 is the median individual effective concentration of peginterferon and n is the power of the Hill function representing the second order sensitivity to changes in interferon levels for blocking production. EC 90 , which better estimates the antiviral sensitivity than EC 50 , can be derived by:
Peginterferon concentrations were integrated into the model, using a standard pharmacokinetic model:
ðe Àk e t À e Àk a t Þ
where the bio-available injected dose and volume of distribution are coupled into the parameter C 0 ¼ FD=V d , k a is the absorption rate from the injection site and k e is the clearance rate from the serum circulation. Peg-interferon half-life in serum was calculated from the clearance rate:
Note that since e(t) is not constant in time, the analytical solution of 
Parameter estimates
First-phase viral decline was estimated according to the maximal decline during first 3 days of the treatment, in log 10 IU/ml. Second-phase viral decline slope was calculated by viral decline during second and third weeks of the treatment, as log 10 IU/ml per week.
Before the treatment, the intrinsic clearance of virions is assumed to be in equilibrium with viral production in time scale of days, as well as equilibrium between infection rate and loss rate of infected cells, therefore giving rise to a steady state. The initial conditions can therefore be estimated. Viral load before the beginning of the treatment was measured, V 0 , and from the steady-state assumptions we obtain
From the steady-state condition and using the V 0 data we can also set b ¼ dcd/(sp À cdV 0 ). In addition, we had set the next parameters to fixed values P ¼ 10 (virus/cell production rate), d ¼ 0.01 (per day, target cells death rate), s ¼ 1 Â e 9 (target cells/day production rate) according to the literature ( [23, 31, 32] ). We verified that changing these parameters over a number of orders of magnitude does not significantly change the results of our estimates.
Using nonlinear regression analysis (Madonna, Berkeley), we began by fitting peg-IFN pharmacokinetic data for each patient, thus estimating the absorption rate, k a , clearance rate, k e , and absorbed dose, C 0 . Based on the pharmacokinetic profile, we fitted viral load kinetics by the combined viral dynamic/pharmacodynamic model, individually for each patient, estimating the viral kinetics parameters -viral clearance rate, c, infected cell death rate, d, and the pharmacodynamic parameters Nhill coefficient, n, and EC 90 . From these, we estimated IFN max /EC 90 and days interferon is over EC 90 .
Statistical analysis
The nonparametric Mann-Whitney U-test was used to test the significance of differences in distribution of continuous pharmacokinetic and pharmacodynamic variables between subgroups of patients (e.g. race). The nonparametric Spearman test was used to test the significance of correlation between continuous variables. We compared parameters in four groups of therapeutic outcome (nonresponder, viral breakthrough, REL, and SVR) by ANOVA test (SPSS 13.0). Significance was assumed at P < 0.03. Results are presented as mean AE standard deviation. To evaluate pharmacodynamic and viral kinetic parameters (IFN max /EC 90 , days interferon over EC 90 and viral load decline at day 3) as predictors of treatment outcome, we calculated the positive and negative predictive value (NPV).
Results
HCV viral kinetics prediction of therapeutic response among HIV/HCV co-infected patients
When we examined the predictive ability of HCV viral kinetics for therapeutic response, within each race group, there were differences in viral kinetics as function of the result of treatment. At all time points we examined, nonresponders had significantly lower HCV viral load decline when compared to those who experience viral breakthrough, relapse or sustained virologic response ( Fig. 1c ). In addition, absolute HCV viral load on days 3 and 28 was statistically significantly lower for patients with SVR compared to patients with relapse (P ¼ 0.05).
There was no significant difference in viral kinetics between the relapsers and viral breakthrough groups.
In order to better understand the relationship between early HCV kinetics and therapeutic response rates we analyzed the role of several HCV kinetic parameters as predictors of SVR (see Fig. 1e -h). All patients who achieved SVR (both African-Americans and Caucasians), experienced a larger than 1.0 log decline in HCV RNA at day 3 (P ¼ 0.005), as well as an absolute HCV viral load of less than 5.0 log IU/ml at day 28 (P ¼ 0.002), suggesting that a rapid decline in viral load earlier during therapy may be predictive of SVR ( Fig. 1e-f ). The combination of a 1 log viral decline at day 3 with viral load less than 5 log IU/ml at day 28 gives NPV 100% and positive predictive value (PPV) 100% in our study.
When we examined the slope of the second-phase decline ( Fig. 1g-h ), those patients who achieved an SVR, irrespective of their race, all had a second-phase slope faster than 0.3 log/week (NPV 100%, P ¼ 0.005), but the PPV for the second-phase slope was not as good. The rebound in viral load between days 3 and 7 was not predictive of the therapeutic response. Notably, serum IFNa concentrations at all measured time points, as well as the pharmacokinetic parameters, maximum concentration of interferon and interferon half-life were comparable for all therapeutic end-point groups: SVR, REL, viral breakthrough, or nonresponders (Figs 1d and 2 and Table 2 ).
Pharmacodynamic parameters as combination predictors of therapeutic response
In order to better understand the relationship between HCV viral decline and IFNa pharmacokinetics, we have fit the viral decline as function of the drug concentration data. This was achieved by an ODE mathematical model of pharmacokinetics combined with viral dynamics with a linking pharmacodynamic function as described in the Methods section. The fit of both the viral kinetics and the pharmacokinetics was good as can be seen in Fig. 3 HIV/HCV co-infected patients. Sustained viral response (SVR, green circles) can be predicted in our study with NPV 100% and PPV 100% by the combination of HCV RNA decline larger than 1.0 log IU/ml at day 3 (X-axis in a and b) and HCV RNA load below 5.0 log IU/ml at day 28 (Y-axis in a and b). Nonresponders (NR, black diamonds) have lower decline in viral load than patients with viral breakthrough (viral breakthrough, red squares) and patients with relapse (REL, blue triangles). Also, a second-phase viral decline slope (Y-axis in c and d) slower than 0.3 log/week is predictive of lack of SVR, but the transient rebound at days 3-7 (X-axis in c and d) is not correlated with therapeutic response). In addition, it is possible to observe the faster decline in Caucasians (f and h) as compared to African-Americans (e and g), in both first phase decline at day 3 and second-phase decline, as well as viral load at day 28. Consequently, from the nonlinear fits, we obtained estimates of the pharmacodynamic parameters EC 50 (or EC 90 ), describing the sensitivity of the virus to interferon, and the Nhill coefficient describing the secondorder sensitivity to changes in interferon concentration. Although, as mentioned above, the interferon pharmacokinetics were similar among all different groups of patients ( Fig. 2a and c) , we nevertheless find that EC 50 is significantly (P < 0.03) lower for Caucasians (3.2 log pg/ml) as compared to African-Americans (3.6) (see Fig. 2b and Table 2 ). Thus suggesting that the differences in viral kinetics between the races is not due to abnormal pharmacokinetics of IFNa but due to lower sensitivity of the virus, or most probably virus-related host factors, to 2444 AIDS 2009, Vol 23 No 18 is observed between any of the groups. EC 50 (b) is significantly (P < 0.03) higher for African-Americans as compared to Caucasians but is not predictive of therapeutic response. Nhill (d) is slightly but not significantly higher for African-American versus Caucasians. The combined pharmacokinetic/pharmacodynamic measures -C max /EC 90 (e) and days interferon level is above EC 90 during the first week (f)are higher for Caucasians relative to African-Americans and are predictive of SVR. For comparison sake we also show here the parameters values obtained from our analysis of the data obtained for HCV mono-infected Caucasians treated with peg-IFNa2b 1.0 mg/kg [35] . Mono-infected patients show better C max /EC 90 properties than co-infected patients. ART, antiretroviral therapy; ETR, end-of-treatment responders; MSM, men having sex with men; NPV, negative predictive value; PPV, positive predictive value; SVR, sustained virologic responders; VB, viral breakthrough.
IFNa in African-Americans. There was no statistically significant difference in the Nhill coefficient between Caucasians and African-Americans (see Table 2 and Fig. 2d ), although there was a trend for lower Nhill in Caucasians (1.8) as compared to African-Americans (2.6).
As to the effect of pharmacodynamics on therapeutic response, there were no statistical differences in relation to either the EC 50 (or EC 90 ) or Nhill coefficients among the different therapeutic response groups: nonresponders, viral breakthroughs, relapsers, or SVR. Nevertheless, when we calculated the number of days for which the predicted concentration of IFNa (see Fig. 3 ) remained above the EC 90 level, 80% of Caucasians (4/5) and 50% of African-Americans (1/2) who had maintained IFNa concentration above Ec 90 for at least 1 day during the first week achieved SVR (Fig. 2f ). Moreover, none of the African-American (10) or Caucasian (5) patients who did not achieve an interferon C max concentration above their own EC 90 level had achieved SVR (NPV 100%) (see Fig. 2e ).
HIV/HCV co-infected African-Americans have slower viral kinetics but similar pharmacokinetics when compared to Caucasians
The baseline characteristics for study patients enrolled are shown in Table 1 . There were four patients on abacavir; of these two were nonresponders, one was a relapser, and the other was SVR. All patients received similar doses of ribavirin throughout the study and no one was dosereduced for toxicity. The average liver fibrosis score determined by Ishak scale was 2.3 for African-Americans and 2.1 for Caucasians. Moreover, of the three patients who were infected with mixed genotype 1, one each achieved nonresponse, relapse, and SVR. The study patients were predominantly male and comprised of 10 Caucasians (43%), 12 African-Americans (52%), and one black Hispanic (5%), who was grouped with the African-Americans for this analysis. Baseline HCV and HIV viral levels and baseline CD4 þ T-cell counts were similar between the groups. Most of the patients had undetectable HIV viral load. We found no correlation between HIV viral load (only nine patients had detectable HIV viral load at baseline, of which three were relapsers and four were SVR and only two were nonresponders) and HCV therapeutic outcome. All patients had a similar HCV viral kinetic pattern, although with a different behavior (see Fig. 1 ), with a rapid first-phase decline in days 0-3, followed by a transient viral rebound at days 3-7 after each injection (in conjugation with the decline in interferon serum levels at the same time), as observed here in the first week as well as in the second week when mid-week samples were available. Consequently, a slower second-phase viral decline slope is observed from one week to the next that is consistent as long as can be observed above the limit of detection.
When we examined the HCV viral kinetics among African-Americans and Caucasians, the mean decline in HCV viral load at 4 weeks was significantly (P ¼ 0.012) smaller (1.01 AE 0.99 log) among African-Americans compared to the decline seen among Caucasians (1.99 AE 0.71 log) ( Fig. 1 and Table 2 ). Also, after 12 weeks of treatment, African-Americans had a mean HCV decline of 1.92 AE 1.2 log which was significantly (P ¼ 0.026) smaller than a mean HCV decline of 3.23 AE 0.78 log observed among Caucasians. This translated to a lower SVR rate in African-Americans (1/13, 7.6%) as compared to Caucasians (4/10, 40%).
The significant difference in HCV RNA decline between Caucasians and African-Americans starts already as early as days 1, 3, and 7 as seen in Figs 1 and 3 . First-phase HCV viral decline was significantly smaller among African-Americans (mean 0.64 AE 0.33 log IU/ml) than Caucasians (mean 1.104 AE 0.377; P ¼ 0.015). African-Americans also had slower second-phase viral kinetics (mean 0.245 AE 0.267 log/week) than Caucasians (mean 0.52 AE 0.25; P ¼ 0.006) ( Table 2 and Fig. 1e-h) . With respect to end-of-week rebound (days 3-7), there was no significant difference in the magnitude of the rebound or the proportion of patients who experienced a viral rebound between the two groups (P > 0.05). However, when we investigated the role of IFNa to explain the differences in HCV viral kinetics, we found that the pharmacokinetics of IFNa, in terms of maximal drug concentration and drug half-life, were comparable between African-Americans and Caucasians (Figs 1b and 2 and Table 2 ). With respect to baseline CD4 þ T-cell counts between the two groups, African-Americans had similar levels compared to that of Caucasians (538 AE 313 versus 646 AE 168 cells/ul; P ¼ 0.27).
Comparison of pharmacokinetics and viral kinetics in HIV/HCV co-infected patients versus HCV mono-infected patients
The mean reduction from baseline in HCV RNA after 4 weeks and 12 weeks of treatment for all the HIV/HCV co-infected patients in our study was 1.38 AE 0.92 and 2.65 AE 1.24 log IU/ml, respectively. In a similar study treating mono-infected HCV patients with the same treatment regimen [34] the mean decline in HCV viral load at 4 weeks was 1.89 AE 0.577 and a 3 log decline after 8 weeks of treatment, significantly higher than observed with our HCV/HIV co-infected patients. However, the comparison of viral kinetics and treatment response rates between HIV/HCV co-infected patients and HCV mono-infected patients is questionable due to potential differences in the pharmacokinetics that could differ between the populations.
On the contrary, the combined pharmacodynamic parameters, for example C max /EC 90 , should allow a more reliable comparison between the two populations, since they normalize the potential differences in pharmacokinetics. In fact, a similar pharmacodynamic analysis was performed by us on HCV mono-infected patients treated with peg-interfrona2b 1.0 mg/kg qw in a study by Bruno et al. [35] . Unfortunately, the interferon C max concentration and EC 90 coefficient cannot be compared between the studies due to the different doses used. We have nevertheless compared the interferon half-life observed in our patients to that found for HCV mono-infected patients and found no significant difference (see Fig. 2c ). The Nhill 2446 AIDS 2009, Vol 23 No 18 coefficient was higher in mono-infected Caucasian patients (3.7) as compared to the HIV/HCV Caucasian patients in our study (1.8) (see Fig. 2d ). Furthermore, we found a higher proportion (80%) of HCV mono-infected Caucasian patients were able to achieve C max levels of IFNa over their individual EC 90 as compared to HIV/ HCV co-infected Caucasian individuals in our study (50%) ( Fig. 2e ).
Discussion
Our study suggests that African-American HIV/HCV co-infected individuals treated with peg-IFNa2b and ribavirin have slower HCV viral kinetics compared to coinfected Caucasians due to a lower pharmacodynamical sensitivity, EC 50 , to IFNa. Our results also imply that the best predictors of SVR in HIV/HCV co-infected individuals were viral kinetics, as early as the viral decline at day 3 of treatment, and pharmacodynamic characteristics of the patients, in particular the ability to maintain levels of interferon over the EC 90 levels for a longer period of time. As a result, African-American individuals experienced a lower rate of SVR when compared to that of Caucasians.
Although this depressed response to therapy among African-Americans has been described among HCV mono-infected individuals, the factors which may contribute to this adverse outcome are not well characterized.
Since HIV/HCV co-infected patient population in the US consist of a higher proportion of African-American origin, understanding the underlying mechanisms involved in lower response rates to interferon-based combination therapy for HCV is important to optimize therapy.
In our study, a rapid decline in HCV viral load was seen during first-phase (days 1-3) viral kinetics among those who achieved sustained virologic response (in both African-Americans and Caucasians). Additionally, all SVRs experienced a significantly faster second-phase slope of viral decline compared to nonresponders. These results are consistent with those obtained when HCV mono-infected individuals were treated with peg-IFNa2b and ribavirin [34] . Furthermore, these results suggest that the mechanisms that determine the rate of HCV viral decline may play a role in determining sustained virologic response in HIV/HCV co-infected individuals. Our results demonstrate the clinical significance of monitoring early viral kinetics in predicting virologic response to therapy with peg-IFNa2b and ribavirin among HIVHCV co-infected individuals. However, the mechanisms involved in a lack of early virologic response among these individuals were not clearly understood. Although one-log viral decline and day 28 HCV viral load offers a 100% NPVand PPV in our study, these results need to be validated in larger clinical trials for clinical utility.
In order to understand the role of achievable levels of IFNa in the serum of these individuals on HCV viral decline, we measured the levels of IFNa in serum at frequent intervals after administration of peg-IFNa2b and ribavirin. Whereas the pharmacokinetics of IFNa were comparable in all groups, differences were observed in pharmacodynamic properties among those who achieved SVR. Notably, all patients who achieved SVR maintained a serum concentration of IFNa above the Ec 90 levels for a longer period of time compared with the nonresponder groups, suggesting that maintaining levels above EC 90 is essential in achieving sustained virologic response. This finding is further corroborated by the observation that among the HCV mono-infected patients that we examined, a higher proportion was able to maintain levels of IFNa over the EC 90 levels consistent with the higher rate of SVR in this group. When different pharmacodynamic parameters were examined among HIV/HCV co-infected and mono-infected individuals, a higher ratio of IFNa maximum concentration to EC 90 levels was noted among HCV mono-infected patients and those co-infected patients who achieved an SVR. These results suggest that maintaining levels of IFNa concentrations above the levels that is required for maximal antiviral effect is vital in clearance of HCV. Since the maximal antiviral effect of IFNa depends on both viral and host factors, the clearance of HCV depends on the sensitivity of virus to respond to interferon and the ability of interferon to induce host response to clear the virus. This study illustrates the fact that antiviral effect in vivo is a collective function of viral sensitivity to IFNa and the ability of IFNa to induce host factors that result in clearance of HCV. Our data suggest that the pharmacodynamic parameters can accurately estimate the antiviral efficacy of IFNa and possibly shed light into the mechanisms for lack of HCV clearance among HIV/ HCV co-infected African-American individuals.
Our study highlights possible parameters related to viral kinetics and pharmacodynamics, which may explain the difference in treatment efficacy among HIV/HCV coinfected patients and in African-Americans compared with Caucasians. This study extends our understanding about the mechanisms of nonresponse to interferon-based therapy among HIV/HCV co-infected individuals. On the basis of our findings, it is highly probable that HIV/HCV co-infected African-Americans have a higher threshold for maximal antiviral response including which results in lower rates of SVR. Further studies will evaluate whether this higher threshold is as a result of differential host response to interferon or other antiviral factors conferring resistance to interferon. Although one study has used a unique approach based on gene expression profiles of peripheral blood mononuclear cells (PBMCs) of HCV mono-infected African-Americans and Caucasians suggesting differential mechanisms underlying lack of SVR, further studies are required among HCV/HIV coinfected individuals to delineate the mechanisms for nonresponse to interferon [36] .
Whereas our small sample size may limit the conclusions that can be drawn, our findings do suggest that rapid viral decline as well as pharmacodynamic parameters should be considered as valuable factors in predicting therapeutic response. Given these findings, future studies investigating the effects of intensification of treatment by utilizing an increased dosing regimen or a conjugated vehicle to maximize the achievable levels of interferon over EC 90 levels, may have a significant impact on improving the rates of therapeutic response among co-infected HIV/HCV affected African-American individuals.
